Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

enVVeno Medical (NVNO) EBITDA (2017 - 2020)

enVVeno Medical has reported EBITDA over the past 4 years, most recently at -$4.2 million for Q4 2020.

  • For Q4 2020, EBITDA fell 80.88% year-over-year to -$4.2 million; the TTM value through Dec 2020 reached -$9.1 million, down 19.02%, while the annual FY2025 figure was -$20.9 million, 12.28% up from the prior year.
  • EBITDA for Q4 2020 was -$4.2 million at enVVeno Medical, down from -$1.9 million in the prior quarter.
  • Over five years, EBITDA peaked at -$1.2 million in Q2 2017 and troughed at -$4.2 million in Q4 2020.
  • A 4-year average of -$2.0 million and a median of -$1.8 million in 2017 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 152.63% in 2018 and later skyrocketed 37.02% in 2019.
  • Year by year, EBITDA stood at -$1.9 million in 2017, then increased by 6.73% to -$1.8 million in 2018, then decreased by 27.8% to -$2.3 million in 2019, then tumbled by 80.88% to -$4.2 million in 2020.
  • Business Quant data shows EBITDA for NVNO at -$4.2 million in Q4 2020, -$1.9 million in Q3 2020, and -$1.5 million in Q2 2020.